{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T02:58:39Z","timestamp":1772506719577,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.jcjo.2014.03.004","type":"journal-article","created":{"date-parts":[[2014,5,24]],"date-time":"2014-05-24T02:16:26Z","timestamp":1400897786000},"page":"273-278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Long-term results of fluocinolone acetonide intravitreal implant in Beh\u00e7et intractable posterior uveitis"],"prefix":"10.1016","volume":"49","author":[{"given":"Eun Kyu","family":"Oh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Kyoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeong Gon","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2014.03.004_bib1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ohc.2004.06.010","article-title":"Anterior segment complications following periocular and intraocular injections","volume":"17","author":"Castellarin","year":"2004","journal-title":"Ophthalmol Clin North Am"},{"key":"10.1016\/j.jcjo.2014.03.004_bib2","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/00055735-200012000-00016","article-title":"Ocular complications of topical, peri-ocular and systemic corticosteroids","volume":"11","author":"Carnahan","year":"2000","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.jcjo.2014.03.004_bib3","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/00006982-200410000-00002","article-title":"Risks of intravitreous injection: a comprehensive review","volume":"24","author":"Jager","year":"2004","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2014.03.004_bib4","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0002-9394(03)00483-5","article-title":"Acute endophthalmitis following intravitreal triamcinolone acetonide injection","volume":"136","author":"Moshfeghi","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2014.03.004_bib5","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2014.03.004_bib6","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1167\/iovs.04-0792","article-title":"Down-regulation of IFN-\u03b3\u2013producing CD56+ T cells after combined low-dose cyclosporine\/prednisone treatment in patients with Beh\u00e7et\u2019s uveitis","volume":"46","author":"Ahn","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2014.03.004_bib7","doi-asserted-by":"crossref","first-page":"6133","DOI":"10.4049\/jimmunol.175.9.6133","article-title":"CD8brightCD56+ T cells are cytotoxic effectors in patients with active Beh\u00e7et\u2019s uveitis","volume":"175","author":"Ahn","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jcjo.2014.03.004_bib8","first-page":"3569","article-title":"Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device","volume":"41","author":"Jaffe","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jcjo.2014.03.004_bib9","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3109\/09273940903267936","article-title":"Fluocinolone acetonide intravitreal implants in Vogt-Koyanagi-Harada disease","volume":"17","author":"Yousuf","year":"2009","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jcjo.2014.03.004_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/09273940802023778","article-title":"Treatment of serpiginous choroiditis with intravitreous fluocinolone acetonide implant","volume":"16","author":"Rajeev","year":"2008","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jcjo.2014.03.004_bib11","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ophtha.2008.10.024","article-title":"Management of sympathetic ophthalmia with the fluocinolone acetonide implant","volume":"116","author":"Vinit","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2014.03.004_bib12","series-title":"Duane\u2019s Clinical Ophthalmology","first-page":"17","article-title":"Ocular manifestations of connective tissue (collagen) diseases","author":"Gold","year":"1989"},{"key":"10.1016\/j.jcjo.2014.03.004_bib13","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2014.03.004_bib14","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3109\/09273948.2011.580075","article-title":"Cytomegalovirus endotheliitis after fluocinolone acetonide (Retisert) implant in a patient with Beh\u00e7et uveitis","volume":"19","author":"Unchul","year":"2011","journal-title":"Ocul. Immunol. Inflamm"},{"key":"10.1016\/j.jcjo.2014.03.004_bib15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1756-185X.2010.01462.x","article-title":"How to deal with Behcet\u2019s disease in the daily practice","volume":"13","author":"Davatchi","year":"2010","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jcjo.2014.03.004_bib16","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ajo.2008.08.038","article-title":"Long-term efficacy and safety of low-dose interferon alpha-2a therapy in severe uveitis associated with Beh\u00e7et disease","volume":"146","author":"Gueudry","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2014.03.004_bib17","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/rheumatology\/kem101","article-title":"Long-term efficacy of infliximab in refractory posterior uveitis of Beh\u00e7et\u2019s disease: a 24-month follow-up study","volume":"46","author":"Niccoli","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.jcjo.2014.03.004_bib18","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1196\/annals.1423.050","article-title":"Anti-TNF-alpha therapy in seven patients with Beh\u00e7et\u2019s uveitis: advantages and controversial aspects","volume":"1110","author":"Tognon","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jcjo.2014.03.004_bib19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/09273940591004232","article-title":"Vitrectomy for persistent panuveitis in Behcet\u2019s disease","volume":"13","author":"Ahn","year":"2005","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jcjo.2014.03.004_bib20","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s10792-009-9332-9","article-title":"CMV retinitis after intravitreal triamcinolone acetonide injection in a patient with Behcet\u2019s uveitis","volume":"30","author":"Tugal-Tutkun","year":"2010","journal-title":"Int Ophthalmol"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418214000805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418214000805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T20:03:27Z","timestamp":1757793807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418214000805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0008418214000805"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2014.03.004","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term results of fluocinolone acetonide intravitreal implant in Beh\u00e7et intractable posterior uveitis","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2014.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}